HCC Program

About Arcellx

Arcellx is a mission-driven biotech founded in 2014 to advance humanity by engineering safer, more effective, and broadly accessible cell therapies. Its primary achievement is the development of a novel, fully synthetic D-Domain technology, which underpins its two therapeutic platforms: the single-infusion ddCAR and the dosable, controllable ARC-SparX system. The company's strategy leverages high-value partnerships, most notably a global collaboration with Kite Pharma, to accelerate the development and commercialization of its lead candidate, anito-cel, for relapsed/refractory multiple myeloma, while advancing a broader pipeline in hematologic malignancies, solid tumors, and autoimmune conditions.

Therapeutic Areas

Other Hepatocellular Carcinoma Drugs